Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753688 · ClinicalTrials.gov registry record · Phase 3
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT00753688: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00753688 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 369 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00753688, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
Primary Outcome
PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. The diagnosis of progression was based on tumor measurements, according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria, by independent radiologic assessment. The Kaplan-Meier method was used for PFS estimates.
Interventions
- DRUG Placebo
- DRUG PAZOPANIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00753688 record still lists
NCT00753688 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00753688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00753688 about?
NCT00753688 is a clinical study titled "Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy". A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
What is the current status of trial NCT00753688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2008-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00753688?
The interventions under investigation include: Placebo (DRUG), PAZOPANIB (DRUG).
Who is sponsoring clinical trial NCT00753688?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00753688's enrollment target sits among peer trials
369 995th of 2000 higher than 1,005 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia